PD-1 monoclonal antibody
- Generic Name
- PD-1 monoclonal antibody
SCRT + mFOLFOX6 + PD-1 Antibody + Targeted Therapy for HIgh-Risk pMMR/MSS Rectal Cancer
Phase 2
Recruiting
- Conditions
- Rectal AdenocarcinomaHigh-Risk CancerMSS
- Interventions
- Radiation: Short-Course RadiotherapyDrug: mFOLFOX6 regimenProcedure: Surgical resection
- First Posted Date
- 2025-04-03
- Last Posted Date
- 2025-05-14
- Lead Sponsor
- Sixth Affiliated Hospital, Sun Yat-sen University
- Target Recruit Count
- 49
- Registration Number
- NCT06908031
- Locations
- 🇨🇳
Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China
SBRT + PD-1 Monoclonal Antibody in Unresectable Colorectal Liver Metastases
Phase 3
Recruiting
- Conditions
- Colorectal CancerLiver Metastases
- Interventions
- First Posted Date
- 2025-01-27
- Last Posted Date
- 2025-05-13
- Lead Sponsor
- Jun Huang
- Target Recruit Count
- 24
- Registration Number
- NCT06794086
- Locations
- 🇨🇳
Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China
Neoadjuvant Long-course Chemoradiotherapy Followed by Immunotherapy for Locally Advanced Mid-low Rectal Cancer
Phase 2
Recruiting
- Conditions
- Locally Advanced Rectal Cancer
- Interventions
- First Posted Date
- 2024-07-09
- Last Posted Date
- 2024-07-11
- Lead Sponsor
- Peking University People's Hospital
- Target Recruit Count
- 30
- Registration Number
- NCT06493240
- Locations
- 🇨🇳
Peking University People's Hospital, Beijing, Beijing, China
A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma and Other Solid Tumors
Phase 2
Recruiting
- Conditions
- Nasopharyngeal CarcinomaNon-small Cell Lung CancerSolid Tumor
- Interventions
- First Posted Date
- 2024-06-26
- Last Posted Date
- 2025-05-07
- Lead Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
- Target Recruit Count
- 332
- Registration Number
- NCT06475300
- Locations
- 🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Unresectable Locally Advanced or Recurrent Metastatic Triple-negative Breast Cancer
Phase 2
Recruiting
- Conditions
- Triple-negative Breast Cancer
- Interventions
- First Posted Date
- 2024-06-24
- Last Posted Date
- 2025-05-07
- Lead Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
- Target Recruit Count
- 52
- Registration Number
- NCT06471205
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
Synergistic Effects of PD-1 Antibody and Chemotherapy Followed by Surgery-centric Local Treatment in Patients with Limited-metastatic Gastric Cancer (ROSETTE)
Phase 2
Recruiting
- Conditions
- Gastric CancerGastroEsophageal Cancer
- Interventions
- Procedure: Local treatment (Surgical)Drug: XELOX Chemotherapy RegimenProcedure: Local Treatment (Non-surgical)
- First Posted Date
- 2024-06-21
- Last Posted Date
- 2024-12-31
- Lead Sponsor
- Shanghai Zhongshan Hospital
- Target Recruit Count
- 84
- Registration Number
- NCT06468280
- Locations
- 🇨🇳
Zhongshan Hospital, Fudan University, Shanghai, Shanghai, China
🇨🇳Zhongshan Hospital Fudan University, Shanghai, Shanghai City, China
A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Extensive-stage Small Cell Lung Cancer
Phase 2
Recruiting
- Conditions
- Extensive-stage Small-cell Lung Cancer
- Interventions
- First Posted Date
- 2024-05-31
- Last Posted Date
- 2025-05-07
- Lead Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
- Target Recruit Count
- 36
- Registration Number
- NCT06437509
- Locations
- 🇨🇳
Shanghai East Hospital, Shanghai, Shanghai, China
A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma and Other Solid Tumors
Phase 2
Recruiting
- Conditions
- Head and Neck Squamous Cell Carcinoma
- Interventions
- First Posted Date
- 2024-05-31
- Last Posted Date
- 2025-05-07
- Lead Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
- Target Recruit Count
- 46
- Registration Number
- NCT06437522
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
A Study of BL-M07D1 Combination Therapy in Patients With Unresectable Locally Advanced or Metastatic HER2-positive Gastric or Gastroesophageal Junction Adenocarcinoma
Phase 2
Not yet recruiting
- Conditions
- HER2-positive Gastric or Gastroesophageal Junction Adenocarcinoma
- Interventions
- First Posted Date
- 2024-05-21
- Last Posted Date
- 2024-07-18
- Lead Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
- Target Recruit Count
- 120
- Registration Number
- NCT06423885
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
Allogeneic Gamma-delta T Cells Combined With Targeted Therapy and Immunotherapy in a Phase 1 Clinical Trial of Hepatocellular Carcinoma Resistant to PD-1 Monoclonal Antibody
Early Phase 1
Not yet recruiting
- Conditions
- Hepatocellular Carcinoma
- Interventions
- First Posted Date
- 2024-04-15
- Last Posted Date
- 2024-04-15
- Lead Sponsor
- Beijing 302 Hospital
- Target Recruit Count
- 18
- Registration Number
- NCT06364800
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath